Breast cancer research studies by attending physicians on staff within Inova Cancer Services and Inova Women's Services
Last updated December 2011
This list of open research trials is meant to be a general information resource only. This information is updated on a regular basis. It should not replace information given by your physician. These studies may close without warning.
In addition to the consent forms for these studies, additional general disease information and trial search information can be found at the National Cancer Institute site, www.cancer.gov. The U.S. government has a clinical trials site (www.clinicaltrials.gov) with helpful information for patients and trials categorized by specific therapeutic areas.
Frequently asked questions about clinical trials
For questions regarding the status of an individual study, please contact the person listed with each individual study.
Translational Research
| Protocol/Organization |
Study Title/Purpose |
Status |
Inova/George Mason University
Transitional Research Institute |
Cancer Molecular Profiling Project
Purpose: To study the phosphoproteomic profile of brain, ovarian, colorectal, liver, lung and hematogenous malignancies to classify disease and develop treatments using microarray technology
Principal Investigator: Kirsten Edmiston, MD
Contact Person: Heather Huryk, 703-776-4021 |
Open |
International Genomics
Consortium (IGC) |
The Expression Project for Oncology (expO)
Purpose: To perform gene expression analysis on breast, lung, colon, ovary and prostate tumors and make all data publicly available with no intellectual property restrictions.
Principal Investigator: Kirsten Edmiston, MD
Contact person: Heather Huryk, 703-776-4021 |
Open |
Site: Breast – Ductal Carcinoma in Situ
Site: Breast – Neoadjuvant
| Protocol/Organization |
Study Title/Purpose |
Status |
| ISPY-2 |
ISPY-2 Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis
Purpose: To study multiple novel agents in locally advanced breast cancer patients receiving neoadjuvant chemotherapy.
Principal Investigator: Kirsten Edmiston, MD
Contact Person: Heather Huryk, 703-776-4021; Stacey Banks, 703-208-3148; Kristen Smiley, RN, 703-720-5210 |
Open |
Site: Breast – Adjuvant
| Protocol/Organization |
Study Title/Purpose |
Status |
| US Oncology 07-132 |
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC, for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Principal Investigator: Nicholas Robert, MD
Contact Person: Stacey Banks, 703-208-3148 |
On Hold
|
Site: Breast – Locally Recurrent or Metastatic
| Protocol/Organization |
Study Title/Purpose |
Status |
CALGB 40502
|
A Randomized, Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixebepilone Combined with Bevacizumab, as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Principal Investigator: Mary Wilkinson, MD
Contact Person: Kristen Smiley, RN, 703-720-5210 |
Open |
| CALGB 70604 |
A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Principal Investigator: Mary Wilkinson, MD
Contact Person: Kristen Smiley, RN, 703-720-5210 |
Open |
| US Oncology 08-223 |
A Randomized, Phase III, Double-Blind, Placebo-Controlled, Multi-Center Trial of Daily Everolimus in Combination with Trastuzumab and Vinorelbine, in Pretreated Women with HER2/neu Over-Expressing Locally Advanced or Metastatic Breast Cancer
Principal Investigator: Nicholas Robert, MD
Contact Person: Stacey Banks, 703-208-3148 |
Open |
| US Oncology 09-097 |
A Randomized, Phase III, Open-Label Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab Plus Chemotherapy, in Subjects with HER2- Positive Metastatic Breast Cancer
Principal Investigator: Nicholas Robert, MD
Contact Person: Stacey Banks, 703-208-3148 |
Open |
| US Oncology 09-185 |
2010EAP: An Open-Label, Expanded Access Protocol of Iniparib in Combination with Gemcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer
Principal Investigator: Nicholas Robert, MD
Contact Person: Stacey Banks, 703-208-3148 |
Open |
| SIDE-OUT |
A Pilot Study Utilizing Molecular Profiling by IHC, FISH, DNA Microarray, and Reverse Phase Protein Microarray (RPMA) of Patients' Tumors to Find Potential Targets and Select Treatments, for Patients with Metastatic Breast Cancer
Principal Investigator: Nicholas Robert, MD
Contact Person: Stacey Banks, 703-208-3148 |
Open |
| TRIO 018 (A5481003) |
Phase I/II, Open-Label, Randomized Study of the Safety, Efficacy, and Pharmacokinetics of Letrozole Plus PD 0332991 (Oral CDK 4/6 inhibitor) and Letrozole Single Agent, for the First-Line Treatment of ER Positive, HER2 Negative Advanced Breast Cancer in Postmenopausal Women
Principal Investigator: Nicholas Robert, MD
Contact Person: Stacey Banks, 703-208-3148 |
Open |
Mayo Clinic MC0738
|
The Effect of Anti-depressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study
Principal Investigator: Neelima Denduluri, MD
Contact Person: Stacey Banks, 703-208-3148 |
Open |
